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Abstract: The cystic fibrosis (CF) lung harbours a diverse microbiome and reduced diversity in the CF
lung has been associated with advancing age, increased inflammation and poorer lung function. Data
suggest that the window for intervention is early in CF, yet there is a paucity of studies on the lung
microbiome in children with CF. The objective of this study was to thoroughly characterise the lower
airway microbiome in pre-school children with CF. Bronchoalveolar lavage (BAL) samples were
collected annually from children attending the three clinical centres. Clinical and demographic data
were collated on all subjects alongside BAL inflammatory markers. 16S rRNA gene sequencing was
performed on the Illumina MiSeq platform. Bioinformatics and data analysis were performed using
Qiime and R project software. Data on 292 sequenced BALs from 101 children with CF and 51 without
CF show the CF lung microbiome, while broadly similar to that in non-CF children, is distinct.
Alpha diversity between the two cohorts was indistinguishable at this early age. The CF diagnosis
explained only 1.1% of the variation between the cohort microbiomes. However, several key genera
were significantly differentially abundant between the groups. While the non-CF lung microbiome
diversity increased with age, diversity reduced in CF with age. Pseudomonas and Staphylococcus were
more abundant with age, while genera such as Streptococcus, Porphyromonas and Veillonella were less
abundant with age. There was a negative correlation between alpha diversity and interleukin-8 and
neutrophil elastase in the CF population. Neither current flucloxacillin or azithromycin prophylaxis,
nor previous oral or IV antibiotic exposure, was correlated with microbiome diversity. Consecutive
annual BAL samples over 5 years from a subgroup of children demonstrated diverse patterns of
development in the first years of life.
Keywords: infection; inflammation; microbiota; microbiome; lung; cystic fibrosis; children; paedi-
atrics; bronchoscopy; bronchoalveolar lavage
1. Introduction
Cystic fibrosis (CF) is an autosomal recessive condition with impaired mucociliary
clearance and innate airway defences [1]. Chronic airway infection and inflammation
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culminating in bronchiectasis are the main drivers of the morbidity and mortality of CF [1].
There is good evidence that these processes start early in life, with asymptomatic infants
and pre-school children demonstrating clear associations between the presence of lower
airway infection and inflammation and impaired lung function and structural airway
changes [1,2].
Traditionally, CF airway infections have been known to be caused by a few well-known
bacteria—the ‘usual suspects’. Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus
influenzae, Streptococcus pneumoniae and Stenotrophomonas maltophilia are commonly cul-
tured from CF airway specimens [3]. With the use of 16S ribosomal RNA sequencing, we
now know that the CF airways are inhabited by a much more diverse microbial commu-
nity including ‘emerging species’ and anaerobes never before associated with CF airway
disease [4–8]. Perturbations in the CF airway microbiome are well described. However,
it is unclear what effect these have on the “infection–inflammation–structural damage”
model of CF lung disease [4–13]. Limited studies in young children with CF suggest that
microbial diversity is initially low but increases with age [4,8,10–13]. In contrast, in older
children and adults, diversity decreases with age and declining lung function [4,8,14,15]. In
adults, with advancing lung disease and repeated exposure to antibiotics over an extended
period, dominant CF pathogens emerge in a relatively fixed microbiome with limited
diversity [5,7,16,17].
We aimed to describe the lower airway microbiome in clinically stable pre-school-aged
children with CF, and, using prospectively collected clinical and biological data, explore
relationships between microbiome composition and age, inflammation and antibiotic use.
2. Materials and Methods
This is a prospective observational cohort study, with cross-sectional and longitudinal
components to sample acquisition and data analysis, and is reported in accordance with
the STROBE statement [18].
2.1. Sample Collection
Bronchoalveolar lavage (BAL) was collected from infants and pre-school children
undergoing routine BAL surveillance at three specialist CF centres in Ireland between 2010
and 2016 through the Study of Host Immunity and Early Lung Disease in CF (SHIELD
CF), a prospective longitudinal study established around a clinical BAL surveillance pro-
gramme. Specimens were collected from clinically stable children aged one to six years.
Bronchoscopy was performed through a laryngeal mask airway (LMA) with no suction
applied until below the carina. BAL was performed by instilling 1 mL/kg sterile 0.9% NaCl
per aliquot (up to a maximum of 20 mL) and retrieved using low-pressure suction. The
BAL was performed twice in the right middle lobe and twice in the lingula. All four
samples were pooled. Clinical information regarding the status of the child on the day
of the BAL and on their progress in the preceding year was recorded. Control subjects
without CF undergoing bronchoscopy for clinical reasons, such as a previous haemoptysis,
stridor or cough, were also recruited. No subjects were immunocompromised. These
children were clinically well, as determined by the attending physician, at the time of the
procedure. Negative sampling controls were performed on all bronchoscopes used in this
study by washing 5 mL 0.9% NaCl through the decontaminated bronchoscopes prior to
patient sampling.
2.2. Processing of Clinical Samples
A standardised procedure was used across all three sites for sample acquisition,
processing and storage as previously described [19]. Briefly, BAL was immediately sealed
in a sterile container and transported to the laboratory on ice. An aliquot of BAL fluid was
sent directly for standard microbiological culture. An aliquot of 1.5 mL of each BAL and the
5 mL negative sampling controls were mixed 1:1 with RNALater (Qiagen, Hilden, Germany)
and frozen at −80 ◦C. The remaining amounts of samples were processed as follows: total
Microorganisms 2021, 9, 492 3 of 17
cell counts were performed using trypan blue exclusion and differential cell counts were
carried out manually on cytospin preparations of BAL, stained with haematoxylin and
eosin to facilitate differential cell count by light microscopy. Interleukin-8 (IL-8) levels
were determined by ELISA and neutrophil elastase (NE) levels were determined using an
in-house activity assay. BAL was subsequently centrifuged at 1057× g and the supernatant
aliquoted and frozen at −80 ◦C on site before cold-chain transfer to a central −80 ◦C
biobank for long-term storage.
2.3. DNA Extraction and 16S RNA Gene Sequencing
The DNA extraction process was performed as previously described (Appendix A
supplemental methods) [19] on all samples and negative sampling controls. DNA was
normalised and 16S metagenomic libraries were prepared using primers to amplify the
V3–V4 region of the 16S gene [20], with Illumina adaptors incorporate as described in the
Illumina 16S Metagenomic Library Preparation guide. Molecular-grade water was used as
template for negative procedural controls for the entire library preparation. The pooled
libraries were assessed by an Agilent high-sensitivity DNA kit and quantified by qPCR
using the Kapa Quantification kit for Illumina (San Diego, CA, USA). Libraries were then
diluted, denaturated and sequenced on the Illumina MiSeq (Appendix A supplemental
methods). Three patient samples were run on each sequencing run in order to determine
the coefficient of variation between runs.
2.4. Bioinformatics
Bioinformatic analysis was performed as previously described by Walsh et al. [21].
Briefly, Raw 16S rRNA gene sequencing reads were quality filtered using PRINSEQ with
a sequence read length cutoff of 250 bp, min overlap of 20 bp and Phred score of q20.
Denoising, operational taxonomic unit (OTU) clustering (97% identity), and chimera
removal were performed using USearch (v7-64 bit). OTUs were aligned using PyNAST [22].
Alpha diversity and beta diversity were calculated using Qiime (1.8.0). Taxonomy was
assigned using a BLAST search against the SILVA SSU 123 database [23,24]. Ribosomal
Database Project (RDP) was also used to classify OTUs against GreenGenes database to
corroborate findings using this method [25,26]. The R package decontam was run to assess
contaminant OTUs. Replicates were assessed using Qiime unweighted Unifrac distance
and PCoA models. Further bioinformatics was performed with the phyloseq package in
R.3.2.2 [27].
Sequencing data have been deposited to the European Nucleotide Archive under the
project accession number PRJEB28588.
2.5. Statistical Analysis
All statistical analysis was performed in R 3.2.2. The Kruskal–Wallis test was used
to test for significant changes in alpha diversity between independent groups, while the
Wilcoxon test was used to test for significant changes in alpha diversity within groups
over time. The reported p-values were corrected for multiple comparisons using the
Benjamini–Hochberg (BH) method. The Adonis function in the vegan package was used
to perform permutational analysis of variance (PERMANOVA) to statistically assess the
unweighted UniFrac dissimilarity between groups [28]. The Betadisper package was used
to determine homogeneity in dispersion of variance between cohorts. Correlation analysis
was performed using the Hmisc package [29]. Linear discriminant analysis (LDA) effect
size (LEfSe) was used to identify differentially abundant taxa; an alpha value of ≤0.05
and LEfSe of ≥4.0 were used as the threshold for significance (Table S1) [30]. All data
visualisation was performed using the pheatmap and ggplot2 package [31].
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2.6. Ethics
Ethical approval was granted by the research ethics committee at Children’s Health
Ireland (CHI) at Crumlin (GEN/210/11) and informed consent was obtained from the
parents or guardians of all participating subjects.
2.7. Role of the Funding Source
The funding bodies had no direct role in this study. The corresponding author had full
access to all the data and has final responsibility for the decision to submit for publication.
3. Results
3.1. Patient Characteristics and Sequencing Quality Control
A total of 336 BAL samples were taken from the biobank and, following quality control,
292 (87%) samples provided 16S rRNA gene sequencing reads of sufficient quality to
proceed to analysis (Figure S1). These represented 152 patients; 51 controls (mean age
6.1 years), plus 101 subjects with CF (mean age 3.6 years) from whom there were 241 BALs.
Within the CF cohort, 38 had one BAL, 22 had two BALs, 14 had three, 19 had four, seven
had five and one had six (Table S3). Within the control cohort, all had one BAL. Baseline
characteristics of the groups can be found in Table 1. The mean age of the CF cohort was
lower, reflective of more children with CF having BAL samples taken when younger, with
one centre performing routine BAL from one year of age.
Sequencing generated an average of 198029 (32,493 to 201147) raw reads and an aver-
age of 178840 (29575 to 199709) high-quality reads across all samples after quality control.
This corresponded to a total of 994 OTUs with an average of 90 (28 to 413) OTUs per sample.
In order to establish whether any contamination was evident in our samples, we sequenced
negative controls (Supplementary File F1) and the R package decontam, ran using the
‘combined’ method employing both prevalence in negative controls and frequency as
a function of input DNA concentration, to identify contaminant OTUs (Supplementary
File F2). Negligible contamination was identified. In true samples, contaminant OTUs
represented a mean relative abundance of 0.8% and the two contaminant OTUs assigned to
the genus Pseudomonas were responsible for a miniscule mean relative abundance of 0.07%.
The coefficient of variation between runs based on the three samples repeated on each
run was less than 1 (0.378 ± 0.0933). To further explore the consistency across our runs,
the three replicate samples were analysed using unweighted Unifrac distance and PCoA
models (one-way ANOVA, F statistic = 3.739, p = 0.06577). This satisfied the assumptions
for PERMANOVA (R2 = 0.97203, p = 0.001). Therefore, 97.203% of the between-sample
variance in this model is explained by the original sample. This shows great consistency of
replicates over the runs.
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Table 1. Subject characteristics.
CF Control
Total 101 51
Female (%) 47(46%) 16(31%)
Mean age in years at time of bronchoscopy (±SD) 3.6 (± 1.8) 6.1 (±4.3)(p < 0.001)
Mean (±SD) total BAL cell count 13.8 (± 25.9) × 106/L 6.3 (±16.4) × 10
6/L
(p = 0.02)
Mean (±SD) absolute neutrophil count 4.8 (± 11.0) × 106 /L 1.3 (± 3.3) × 10
6/L
(p = 0.001)
Mean (±SD) IL-8 (pg/mL) 507 (± 297) 249 (± 243)(p < 0.001)
Mean Ln NE (ng/mL) 4.1 (± 1.5) 4.2 (± 0.9)(p = 0.55)
Genotype
Not applicable
F508del homozygous 58 (57%)
F508del heterozygous 22 (22%)
Other 9 (9%)
No data 12(12%)
BAL culture results (total #) (n = 273) (n = 51)
P. aeruginosa (% of total) 12 (4.4%) 1 (1.9%)
S. aureus (% of total) 55 (20.1%) 3 (5.8%)
H. influenzae (% of total) 67 (24.5%) 14 (27.4%)
S. pneumoniae (% of total) 24 (8.8%) 8 (15.7%)
M. catarrhalis (% of total) 8 (2.9%) 4 (7.8%)
S. maltophilia (% of total) 11 (4.0%) 1 (1.9%)
Pancreatic insufficient 81 of 83 with data 98% Not applicable
Mean (±SD) weight z-score at time of bronchoscopy −0.01 (±1.6) No data
Mean (±SD) height z-score at time of bronchoscopy −0.16 (± 2.1) No data
Definition of abbreviations: SD = standard deviation, BAL = bronchoalveolar lavage, Ln = natural log, and NE = neutrophil elastase.
# number.
3.2. Baseline Characteristics of the CF and Non-CF Lung Microbiome
Twenty-nine genera were detected at >1% relative abundance in >10% of samples
in this study (Figure 1). This microbiome was dominated by well-known CF genera such
as Haemophilus, Staphylococcus, Streptococcus, Pseudomonas, and regularly cultured genera,
Neisseria, Moraxella, Actinomyces, Porphyromonas, and also emerging CF microbiome gen-
era, Fusobacterium, Bacteroides, Alistipes, Lachnospiraceae NK4A136 group, Rothia, Prevotella,
Gemella, Granulicatella, Leptotrichia, Capnocytophaga, Lachnospiraceae UCG-004, Alloprevotella,
Veillonella and less regularly reported Bacteroidales S24-7 group, Tepidimonas and Saccharibac-
teria. A significant proportion, 21% of reads in the CF cohort and 15% in the control cohort,
remained unassigned, having no match identified in the reference database (“unassigned”).
In addition, at the genus level, multiple low abundance (<1%) genera cumulatively repre-
sent a significant proportion (26–27%) of the overall microbiome.
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Figure 1. Heatmap of all genera present at ≥1% relative abundance in ≥10% of all samples.
Overall, samples that were culture positive for important CF bacterial genera had
higher relative abundance of those genera when sequenced. Pseudomonas, Staphylococcus,
Haemophilus, Achromobacter, Prevotella and Stenotrophomonas genera were detected in higher
mean relative abundance in samples that were positive for these genera by culture. Veil-
lonella and Streptococcus were present in similar relative abundance across culture positive
and culture negative samples (Supplementary Figure S2). For all genera, bar Achromobacter
and Stenotrophomonas, sequencing detected genera in culture negative samples.
3.3. The overall Diversity of the CF and Non-CF Lower Airway Microbiome Is Broadly Similar
with Significant Differences in Individual Species Abundance
There was no difference between the CF and non-CF microbiome in terms of over-
all alpha diversity when looking at Chao1, Simpson, Shannon, phylogenetic diversity
and observed species (Figure 2A). In terms of beta diversity, unweighted Unifrac princi-
ple coordinate analysis (PCoA) and Betadisper analysis revealed that the dispersion of
variance in the CF group was not heterogenous therefore limiting the assumptions that
can be drawn from the PERMANOVA analysis. Overall the early CF and non-CF lower
airway microbiome had similar alpha and beta diversity. To explore in more detail the
differences between the cohorts, we identified taxa present at >1% relative abundance
that were significantly altered between the cohorts (Figure 2B). Six of nine genera are
more abundant in the control cohort, with Haemophilus and Neisseria the most prominent.
The two exceptions are Staphylococcus and Pseudomonas which are present in significantly
greater relative abundance in the CF lung.
These results suggest that infants and young children with CF, that are asymptomatic
at the time of sample acquisition, have altered abundance of specific genera to that of
similarly aged children without CF. Some of these genera are only emerging as common
colonisers of the CF airway and their importance in CF warrants further investigation.
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Figure 2. Comparison of the CF and control lung microbiome. (A) Violin plots of alpha diversity
measures. (B) The percentage relative abundance of genera which were significantly differentially
abundant between cohorts (i.e., LDA > 4) as determined by LEfSe (error bars show standard error).
3.4. The CF and Control Airway Microbiomes Are Disparately Associated with Age in the First
Years of Life
We performed an age-matched cross-sectional comparison of phylum-level composi-
tion between the two cohorts (Figure 3 and Figure S3). Whilst the lung microbiome of both
populations fluctuated with age, distinguishable patterns were evident in the cohorts. In
the CF cohort, in the older children, there were overall increases in Proteobacteria (+8%)
and unassigned phyla (+8%), while there were decreases in Bacteroidetes (−3%), Firmicutes
(−10%), and Fusobacteria (−5%). In contrast, in the control cohort, there were overall
increases in Actinobacteria (+10%), Bacteroidetes (+9%), and Firmicutes (+2%), while there
were decreases in Fusobacteria (−5%) and Proteobacteria (−17%).
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Figure 3. Cross sectional analysis demonstrating differences, with age, in the average phylum-level composition of the
lower airway microbiota in CF and control BAL from 1 to 6 years of age.
To further explore the changes in the lung microbiome during early childhood, both
cohorts were divided into three age groups: 0–2.5 years; >2.5–5.0 years; and >5 years
(Figure 4). A significant decrease in diversity (PD whole tree) was observed with increased
age in the CF cohort (p < 0.001) (Figure 4A). Conversely, a significant increase in diversity
was observed with increased age in the control cohort (Chao1 p = 0.027 and observed
species p = 0.043). With respect to beta diversity, there were significant dissimilarities in
the CF microbiome between 0–2.5 year olds and 2.5–5 year olds (p = 0.001, R2 = 0.013) and
again between the 0–2.5 year olds and >5 year olds (p = 0.001, R2 = 0.028) (Figure 4B). In
the control cohort, there was significant dissimilarity between 0–2.5 year olds and >5 year
olds only (p = 0.011, R2 = 0.028). Betadisper analysis revealed that there was no statistical
difference between the homogeneity of variance of the age groups in the CF cohort and the
control cohort (F = 1.3622, p = 0.2581 and F = 1.1836, p = 0.315, respectively).
The relative abundances of genera that are altered significantly between the age
groups are presented in Figure 4C. In the control cohort, Streptococcus and Moraxella are
significantly less abundant in the older children. This is in marked contrast to the CF lung
where there are significant changes in the relative abundances of seven genera with age.
Pseudomonas, Staphylococcus and Haemophilus are significantly more abundant in older CF
children while Streptococcus, Veillonella, Neisseria, and Porphyromonas are significantly less
abundant in older CF patients.
Taken together, our results suggest that, in the early years of life, the lung microbiome
of children with CF is developing differently to that of controls.
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Figure 4. Age-associated changes in the microbiome of children with CF and without CF (control). (A) alpha diversity
displayed as violin plots and (B) beta diversity displayed as unweighted UniFrac PCoA plots (ellipses illustrate 80%
confidence intervals) of the lower airway microbiota across three age groups: 0 to 2.5 years old, 2.5 to 5 years old and
over 5 years old. (C) Genera which were significantly differentially abundant (i.e., LDA >4.0) across these same groups, as
determined using LEfSe.
Microorganisms 2021, 9, 492 10 of 17
3.5. The Longitudinal Development of the Lung Microbiome of Children with CF Is Highly
Variable Within and Between Patients
Seven children with CF had a complete dataset, with BAL samples taken for five consec-
utive years from 1 to 5 years of age. This unique subgroup provides potentially important
insights into the development of the lung microbiome in individuals with CF. Across all
seven subjects the composition of the lower airway microbiome, even at phylum level,
is highly variable year to year (Figure 5A), with no clear pattern being evident across
the subjects. Indeed, even within subjects the composition and relative abundance alters
markedly in each consecutive year (Figure 5A). In addition, Chao1, Shannon, and observed
species measures of alpha diversity appear to increase over the first four years of life before
decreasing in the fifth year. However, with the wide variability between patients and
the low number of longitudinal samples in this study, this should be interpreted with
caution (Figure 5B).
Figure 5. Longitudinal development of the CF airway microbiome over 5 years in six patients. (A) Relative phyla abundance
and (B) alpha diversity in the CF lung microbiome.
3.6. The CF Lung Microbiome Is Associated with Inflammatory Markers
Correlation analysis was performed to characterise the relationships between alpha
diversity and inflammatory markers in the CF BAL samples (Table 2). Significant negative
correlations were found between IL-8 and the Simpson (R = −0.21, p = 0.007) measures
of alpha diversity. Similarly, significant negative correlations were found between NE
and both the Simpson (R = −0.16, p = 0.037) diversity measures. No other significant
correlations were identified. Our results indicate a potential link between decreased alpha
diversity and increased inflammation in the CF lung.
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Table 2. Correlations between inflammation and measures of alpha diversity.
Marker Statistic chao1 Simpson Shannon PD Whole Tree Observed Species
log10(ANC)
Adjusted p-value 0.820 0.067 0.261 0.927 0.844
R-value 0.044 −0.164 −0.102 −0.013 0.038
log10(IL-8)
Adjusted p-value 0.927 0.008 0.037 0.067 0.927
R-value −0.011 −0.211 −0.160 0.139 −0.006
NE
Adjusted p-value 0.224 0.037 0.037 0.400 0.224
R-value -0.099 −0.171 −0.159 −0.070 −0.097
Total cell count
Adjusted p-value 0.927 0.215 0.261 0.927 0.927
R-value 0.013 −0.117 −0.097 0.014 0.006
Definitions of abbreviations: log10 = log to the base 10, ANC = absolute neutrophil count, IL-8 = interleukin 8, and NE = neutrophil elastase.
Significance at <0.05 is indicated in italics.
3.7. Greater Antibiotic Use Was Not Associated with Altered Diversity
On the day of bronchoscopy, 33 (13.7%) patients were on prophylactic flucloxacillin
and 21 (8.7%) were on long-term azithromycin treatment. There were no significant dif-
ferences in alpha diversity measures between those treated with either flucloxacillin or
azithromycin relative to those not on antibiotics on the day of the bronchoscopy (Table S2).
While flucloxacillin use did not appear to significantly affect the relative abundance of
Staphylococcus (p = 0.08) or Pseudomonas (p = 0.14), azithromycin use was associated with a
lower relative abundance of Pseudomonas (p = 0.03) (Figure 6).
Figure 6. Comparison of relative abundance of Staphylococcus genus and Pseudomonas genus with
flucloxacillin prophylaxis, and long-term azithromycin treatment, on the day of the bronchoscopy
(Kruskal–Wallis test).
Regarding prior antibiotic exposure, the number of courses of oral antibiotics taken
in the previous year ranged from zero to 12, with a median of four courses, resulting
in a mean duration on oral antibiotics of 42 days (range 0 to 168 days). The number of
admissions for IV antibiotics over the study period ranged from 0 to 6, with a median of
0 courses, representing a median of 0 days on IV antibiotics (range 0 to 43 days). Prior
exposure to antibiotics did not appear to affect the lower airway microbiome as assessed by
BAL during a time of clinical stability. No significant correlations were identified between
total cumulative days on any (intravenous or oral) antibiotics in the previous year and
alpha diversity measures (Table S2).
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4. Discussion
This study presents the largest, robust description of the lower airway microbiome
of young children with CF published to date, and describes changes in the microbiome
with age. Sampling was performed during clinical stability, in a well-defined cohort, across
three centres applying identical BAL acquisition, processing and storage protocols, and a
similar approach to clinical care.
When relative abundance is averaged across the large number of samples in this study
(Figure 1), a pattern consistent with that observed in smaller studies is apparent, i.e., the
lower airway microbiome is dominated by five major bacterial phyla: Proteobacteria, Firmi-
cutes, Bacteroidetes, Fusobacteria and Actinobacteria (with unassigned phyla a significant
sub-group) [4,10,12,13,16,32]. The predominance of Proteobacteria in the lower airway is a
common, but not universal, finding, with a wide variation reported in the relative abun-
dance of the other constituent phyla [4,10,12,13,16,32,33]. The lung microbiome in CF and
control patients was dominated by well-known CF genera such as Haemophilus, Staphylococ-
cus, Streptococcus, Pseudomonas, regularly cultured genera, Neisseria, Moraxella, Actinomyces,
Porphyromonas, and also newer genera emerging as significant components of the CF micro-
biome. Many of these ‘emerging genera’ are anaerobes and have been reported previously
in CF microbiome studies; Fusobacterium, Bacteroides, Alistipes, Lachnospiraceae NK4A136
group, Rothia, Prevotella, Gemella, Granulicatella, Leptotrichia, Capnocytophaga, Lachnospiraceae
UCG-004, Alloprevotella, Veillonella [34–38]. While it is now recognised that anaerobes con-
stitute a significant proportion of the CF lung microbiome, the clinical significance of this
is still uncertain [39].
The CF and control lung microbiome were broadly similar at the phylum level and in
terms of alpha and beta diversity. Unweighted UniFrac analysis revealed only small differ-
ences in beta diversity between the cohorts. There are a small number of studies comparing
BAL samples between control and CF cohorts, and all are limited by small study numbers
and heterogenous cohorts with wide ranging ages and disease severity [6,8,19,33,40]. This
makes comparisons with our findings difficult. It has been shown that the lung microbiome
in children is similar across different disease cohorts, including CF, yet it is possible to
distinguish between the different cohorts based on distinct characteristics of each micro-
biome [6,8,33,40,41]. Alpha diversity is typically higher in non-CF cohorts [6,8,40] and we
did not observe this in our control cohort perhaps due to the young age of the comparison
groups. Despite these similarities, we were able to demonstrates that the CF lower airway
microbiome in early life has some distinctions from the non-CF. At the genus level, we
found nine genera to be of significantly differential abundance between the two cohorts.
Six genera were more abundant in control samples, many of which were anaerobes, and
two genera, Staphylococcus and Pseudomonas, were more abundant in CF subjects. Zeman-
ick et al. also found Staphylococcus and Pseudomonas in greater abundance in the CF lung,
and Prevotella, Veillonella, Neisseria and Porphyromonas higher in non-CF controls, but, in
contrast to our study, Haemophilus was similar in both cohorts [8]. Although the CF lower
airway microbiome is broadly similar to the controls, we have demonstrated differences
between the two microbial communities early in life.
Age was associated with alpha diversity of both the CF and control lung microbiome.
However, where increased diversity was associated with age in the control, decreased diver-
sity was associated with age in CF. There were also disparate age-associated phylum-level
composition shifts in the CF and control microbiome. In CF, a trend towards increasing
abundance of the Proteobacteria phylum (which contains a wide range of Gram-negative
pathogens such as Pseudomonas, Neisseria and Haemophilus) was evident, while the Pro-
teobacteria phylum decreased in abundance in the control microbiome. Similarly, the
Firmicutes (Staphylococcus and Streptococcus containing), Fusobacteria (Fusobacterium) and
Bacteroidetes (Porphyromonas, Bacteroides, Prevotella containing) phyla were disparately as-
sociated with age in the CF and control lung microbiome. Distinctions in the CF and control
lung microbiome with age were also evident at the genus level. Two genera in the control
cohort, Streptococcus and Moraxella, were less abundance with age. As previously reported
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by Laguna et al. [13], our study demonstrates that Streptococcus is one of the predominant
genera that drops in abundance in early childhood in CF. In addition we demonstrate
that relative abundance significantly drops for four other genera, Streptococcus, Veillonella,
Neisseria, and Porphyromonas, as the pre-school years advance. In contrast, we found that
Pseudomonas and Staphylococcus were already demonstrating an emerging dominant pattern
in this young CF cohort.
To date, there have been limited studies focused on longitudinal changes in the lower
airway microbiome in CF. Two studies have reported BAL results from a small number of
children at two different time points and report conflicting results [10,12]. Muhlebach et al.
demonstrated that five of seven patients maintained the same microbial community type
between sampling intervals (ranged from 3.6 to 24 months) [12]. In contrast, Frayman et al.
reported that the beta diversity of serial samples from individual subjects was comparable
to the beta diversity of samples from different subjects [10]. In our study, sequential annual
BAL samples were collected over five years from seven children with CF, aged one to five
years. This unique dataset, for the first time, begins to explain the inconsistencies observed
in previous studies. Here the lower airway microbiome diversity increased over the first
four years of life in young children with CF, before beginning to decline from five years
of age. Although this trend is clear for the summary statistics in the group analysis, the
changes in phylum-level composition for individuals vary considerably between subjects,
and to an equally striking degree, within subjects from year to year. It is clear that sampling
at any given time point will result in very different findings. One might also hypothesise
that the lower airway microbiome cumulatively establishes itself in the first four years of
life, reflected in increasing diversity. Further, this process may begin to reverse or decline
by five years of age with the emergence of CF pathogens in the microbiome. Larger cohorts
of longitudinal data will be required to corroborate these findings.
Our study demonstrates that unassigned OTUs are prevalent in CF BAL samples. In
previous studies, unassigned reads have generally not been reported or they are discarded
prior to analysis [42]. We found one exception, where 41% of reads from bronchial brushing
samples from school-aged children with CF were reported to correspond to unassigned
OTUs [32]. In the present study, comparison of CF versus control BAL samples reveals that
15–22% (higher in the CF cohort) of the relative abundance of the lower airway constitutes
unassigned OTUs. These unassigned reads are unlikely to be from human DNA sources
as we performed 16S rDNA sequencing. They are equally unlikely to be the result of
non-specific amplification as the quality control would rule out any poor quality reads.
This suggests that, as yet, undefined microbes are present in the lung.
Airway inflammation is a central component in the pathogenesis of CF lung disease.
If the microbiome plays a role in CF lung disease, one would expect it to influence, or
be influenced by, airway inflammation. Although we found that in children with lower
diversity, airway inflammation, as measured by NE and IL-8, was higher, our study was
similar to others in that the association was not consistent across different inflammatory
markers and different measures of diversity [10–13]. Further studies are required to un-
derstand if the association becomes more pronounced over time and, if so, to attempt to
determine causality.
Surprisingly, antibiotic exposure did not have a detectable effect on the lower airway
microbiome. Marsh et al. also failed to demonstrate an effect of current antibiotic use on the
lung microbiome of young, non-CF, children [41]. While Zemanick et al. did show a clear
correlation with antibiotic use and reduced diversity, a large proportion of the cohort from
that study were on antibiotics as the BALs were performed for clinical reasons in symp-
tomatic subjects, which included a significant number of adult CF patients [8]. Pittman et al.
demonstrated lower diversity in infants on anti-Staphylococcal antibiotics, a finding we
did not replicate, but which may be partly explained by the use of a broad spectrum
antibiotic (amoxicillin-clavunate) in the Pittman study compared with flucloxacillin in our
study [11]. A relatively small number of infants in our cohort had quite extensive exposure
to intravenous and/or oral antibiotics but this did not differentiate their microbiome from
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those with little or no antibiotic exposure. It may be that, as children were required to be at
a stable baseline for bronchoscopy, previous perturbations of the microbiome had resolved
at the time of sample acquisition [5].
This study has several limitations. Not all subjects had samples taken from one year
of age. This reflected different clinical practices across the different centres. Some subjects
did not have a BAL performed every year. As the SHIELD CF study is based on a clinical
BAL surveillance programme, patients could have their procedure deferred or cancelled if
the attending physician did not feel they were well at the time. Recording prior antibiotic
exposure proved difficult to capture as it is often incompletely recorded in clinical notes.
We cross-checked chart records with available pharmacy and prescription records but
the information is likely incomplete for some patients. The control cohort consisted of
children having a BAL for clinical reasons, and therefore, their underlying condition may
have influenced the findings. It was not possible to obtain sequence data that passed our
stringent quality controls for all samples. However, at 87%, our sequencing success rate is
considerably higher than previous publications [8,10,11,32]. Despite these limitations, our
study has significant strengths. It is the largest study of the CF lower airway microbiome
of young children performed to date, that has both a large control cohort for comparison
and longitudinal samples. We included negative controls of the sampling process, DNA
extraction, library preparation and sequencing protocols in line with the more robust lung
microbiome studies [8,10]. There was a pattern of agreement between our culture data
and sequencing data, keeping in mind that sequencing is a more sensitive method of
detection. Most other CF microbiome studies use sputum samples, arguably a sample with
upper airway representation, and many using BAL have not used the same bronchoscopy
methods used here.
In summary, we have demonstrated that the CF lower airway microbiome in infants
and pre-school-aged children with CF is different to the lower airway of non-CF children.
The CF lower airway microbiome becomes less diverse with age, in contrast to the control
lower airway microbiome. A lower relative abundance of the Streptococcus genus and
several anaerobes and increasing relative abundance of the Pseudomonas and Staphylococcus
genera are associated with age in CF. There are significant differences in microbiome
composition between individuals and within individuals over time. The lower airway
microbiome in clinically stable children with CF was not influenced by prior antibiotic
use in this study, but early changes in its diversity are associated with subtle evidence of
airway inflammation.
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Appendix A. Supplementary Methods
DNA extraction. The DNA extraction process was performed as previously described [19].
Briefly, frozen BAL samples were thawed on ice and centrifuged for 10 min at 10,000× g.
The pelleted material was resuspended in 600 µL of buffer RLT (Qiagen DNA/ RNA
AllPrep Mini kit) and bead beating performed (0.3 g of 180 µM acid washed glass beads;
Sigma Aldrich, Germany) for 30 sec at 5.5 m·sec−1. Supernatant was transferred to a Qiagen
DNA spin column and DNA extracted using the Qiagen DNA/ RNA AllPrep Mini kit.
DNA quantity was determined using the Quant-iT PicoGreen dsDNA assay kit (Invitrogen,
Renfrew, UK) following the manufacturer’s instructions. A saline control sample was
included where the entire DNA extraction process was performed with 1 mL of 0.9% NaCl
as the start material. The DNA extraction protocol was also performed on a subset of
bronchoscope controls; 5 mL of sterile 0.9% NaCl suctioned through the bronchoscopes
and captured in a BAL sample pot prior to the bronchoscopic procedure commencing.
16S rRNA gene sequencing. DNA was normalised and 16S metagenomic libraries were
prepared using primers to amplify the V3–V4 region of the 16S gene [20], with Illumina
adaptors incorporate as described in the Illumina 16S Metagenomic Library Preparation
guide with the following exceptions; Kapa Robust (Kapa Biosystems/ Merck, Watford, UK)
was used in place of Kapa Hifi, the first PCR reaction was performed in a total volume of 50
µL instead of 25 µL and the number of cycles used in the first PCR was increased from 25
cycles to 30. The volume of AMPure XP beads (New England Biolab (NEB), Hitchin, UK)
used in the initial clean-up was scaled up accordingly. Following index PCR and purifica-
tion, the products were quantified using the Qubit high-sensitivity DNA kit (Thermo Fisher
Scientific, Bleiswijk, Netherlands) and pooled equimolarly with approximately 50 samples
per pool. The pooled libraries were assessed by an Agilent high-sensitivity DNA kit and
quantified by qPCR using the Kapa Quantification kit for Illumina (Kapa Biosystems/
Merck millipore, Watford, UK) according to the manufacturer’s guidelines. Libraries were
then diluted and denatured following Illumina guidelines and sequenced on the Illumina
MiSeq using the V2 500 cycle kit.
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Control samples. A saline control sample was included where the entire DNA ex-
traction process was performed with 1 mL of 0.9% NaCl as the start material. The DNA
extraction protocol was also performed on a subset of bronchoscope controls; 5 mL of
sterile 0.9% NaCl suctioned through the bronchoscopes and captured in a BAL sample pot
prior to the bronchoscopic procedure commencing. These samples were carried through
the entire protocol from DNA extraction to sequencing.
Avoidance of upper airway contamination. Because PCR based techniques have such
high-sensitivity contamination of samples from the upper airway can distort attempts
to accurately define the lower airway. By employing an identical protocol in all centres,
which involved passing the bronchoscope through a LMA and avoiding suctioning until
the scope had passed the carina, we believe we obtained samples truly representative of
lung microbiome.
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